Furthermore, Berezovska et al. showed potential therapeutic efficacy of the siRNA-mediated targeting of BMI1 expression, in vitro and in vivo, for treating metastatic prostate cancer [34]. This evidence concerns the gene BMI1 and metastatic prostate carcinoma.